FDA Adverse Event Injury Summary report: N

TOTAL ASR FEM IMP SIZE 47

MDR report key: 2141441 · Received June 22, 2011

Report

Report Number
1818910-2011-11235
Event Type
Injury
Date Received
June 22, 2011
Date of Event
May 23, 2011
Report Date
March 3, 2014
Manufacturer
DEPUY INTERNATIONAL, LTD.
Product Code
KWA
PMA / PMN Number
NA
Removal / Correction Number
Z-1749/1816-2011
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
FI
Reporter Occupation
UNKNOWN

Narratives

Additional Manufacturer Narrative · 1

THIS COMPLAINT IS STILL UNDER INVESTIGATION. DEPUY WILL NOTIFY THE FDA OF THE RESULTS OF THIS INVESTIGATION ONCE IT HAS BEEN COMPLETED.

Additional Manufacturer Narrative · 1

THE ASR PLATFORM WAS VOLUNTARILY RECALLED FROM THE MARKET IN AUGUST 2010, AND THE ASR PRODUCT CODES ARE NOW CONSIDERED INACTIVE. FURTHER INVESTIGATION OF THIS INDIVIDUAL INCIDENT WILL NOT BE UNDERTAKEN, AS THERE IS AN ONGOING INVESTIGATION REGARDING THE ROOT CAUSE(S) AND/OR CORRECTIVE ACTIONS. (B)(4).

Additional Manufacturer Narrative · 1

DEPUY STILL CONSIDERS THE INVESTIGATION CLOSED. IF INFORMATION IS OBTAINED THAT WAS NOT AVAILABLE FOR THE INITIAL MEDWATCH, A FOLLOW-UP MEDWATCH WILL BE FILED AS APPROPRIATE.

Description of Event or Problem · 1

THE PT WAS REVISED TO ADDRESS PAIN, LOOSENING, NOISE, AND ALVAL.

Description of Event or Problem · 1

NEW ETQ RECORD CREATED IN ORDER TO UPDATE ETQ (LEGACY SYSTEM) (B)(4). REASON FOR ORIGINAL COMPLAINT: ASR REVISION BI-LATERAL. ASR HIP RESURFACING SYSTEM (RIGHT); ASR HIP RESURFACING SYSTEM (LEFT). REASONS FOR REVISION FOR BOTH SIDES: COMPONENT LOOSENING, PAIN, NOISE, ALVAL. UPDATE RECEIVED: 20TH FEBRUARY 2014 - MARKED AS LEGAL, ADDED SURGEON: (B)(6) AND ADDED (B)(6) REFERENCE NUMBER. UPDATE RECEIVED: 3RD MARCH 2014 - ADDED WHICH COMPONENT BECAME LOOSE FOR EACH SIDE. BOTH LEFT AND RIGHT SIDE THE CUP BECAME LOOSE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 TOTAL ASR FEM IMP SIZE 47 HIP FEMORAL HEAD KWA DEPUY INTERNATIONAL, LTD. NA 2558688

Patients

Seq Age Sex Outcome Treatment
1 NA Required Intervention